Alnylam Shares HELIOS-B Phase 3 Results on Vutrisiran for ATTR Amyloidosis at ESC Congress

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented at…

Read MoreAlnylam Shares HELIOS-B Phase 3 Results on Vutrisiran for ATTR Amyloidosis at ESC Congress

BostonGene Highlights AI Multiomics Platform and Immune Profiling Advances at World Biomarkers Summit

BostonGene, a leader in AI-driven molecular and immune profiling, will showcase its advanced technologies at the 14th World Clinical Biomarkers & CDx Summit 2024, held from September 3 – 6 in Boston. The summit gathers professionals to advance biomarker-driven clinical…

Read MoreBostonGene Highlights AI Multiomics Platform and Immune Profiling Advances at World Biomarkers Summit

Significant Need for Innovative Endovascular Devices to Treat BTA Disease in CLI Patients

Research by THE SAGE GROUP analyzes the prevalence, characteristics, comorbidities, and outcomes of below-the-ankle (BTA) disease, while also exploring the challenges of endovascular revascularization. BTA (below-the-ankle) disease involves atherosclerotic stenoses or occlusions in foot arteries, including the pedal artery, plantar…

Read MoreSignificant Need for Innovative Endovascular Devices to Treat BTA Disease in CLI Patients